|
|
 Previous Article | Table of Contents | Next Article 
Comparison of three remission induction regimens and two postinduction
strategies for the treatment of acute nonlymphocytic leukemia: a cancer and
leukemia group B study
H Preisler, RB Davis, J Kirshner, E Dupre, F Richards , HC Hoagland, S Kopel, RN Levy, R Carey and P Schulman
Patients with acute nonlymphocytic leukemia were randomized to receive
remission induction therapy consisting of seven days of cytosine
arabinoside and three days of daunorubicin ("7 + 3") or to receive the same
regimen intensified by either the addition of 6-thioguanine or by extension
of the administration of cytosine arabinoside to ten days. Additionally,
all patients were randomized to receive or not to receive cotrimoxazole
antibacterial prophylaxis during the remission induction phase. Neither an
increase in intensity of chemotherapy nor the antibacterial prophylaxis
increased the remission rate above the 53% for patients treated with the
standard "7 + 3" regimen. The second part of this study addressed the issue
of the utility of long-term maintenance chemotherapy. To this end, patients
were randomized to discontinue all treatment after 8 months of maintenance
chemotherapy or to continue maintenance therapy for a total of 3 years.
Although there was a transient increase in the relapse rate for patients
who discontinued therapy, the proportion of long-term remitters was
identical in the two patient groups. Additionally, there is a suggestion of
a survival advantage for patients randomized to discontinue all therapy at
8 months.
Volume 69,
Issue 5,
pp. 1441-1449,
05/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica,
January 1, 2009;
94(1):
102 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Schwarzberg, C. B. Alexander, D. J. DeAngelo, and S. M. Helfgott
A Joint Venture
N. Engl. J. Med.,
June 5, 2008;
358(23):
2496 - 2501.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pigneux, V. Perreau, E. Jourdan, N. Vey, N. Dastugue, F. Huguet, J.-J. Sotto, L. R. Salmi, N. Ifrah, and J. Reiffers
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results
Haematologica,
October 1, 2007;
92(10):
1327 - 1334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe, D. Neuberg, W. Friedenberg, J. M. Bennett, E. Paietta, A. Z. Makary, J. L. Liesveld, C. N. Abboud, G. Dewald, F. A. Hayes, et al.
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
Blood,
January 15, 2004;
103(2):
479 - 485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al.
Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
J. Clin. Oncol.,
February 15, 2003;
21(4):
615 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Hiddemann, W. Kern, C. Schoch, C. Fonatsch, A. Heinecke, B. Wormann, and T. Buchner
Management of Acute Myeloid Leukemia in Elderly Patients
J. Clin. Oncol.,
November 1, 1999;
17(11):
3569 - 3576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Stasi, G. Del Poeta, A. Venditti, M. Masi, E. Stipa, M. Christina Cox, S. Amadori;, F. R. Appelbaum, K. J. Kopecky, and C. L. Willman
Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia
Blood,
July 15, 1998;
92(2):
695 - 697.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe and M. S. Tallman
Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?
Blood,
September 15, 1997;
90(6):
2121 - 2126.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Hann, R. F. Stevens, A. H. Goldstone, J. K.H. Rees, K. Wheatley, R. G. Gray, and A. K. Burnett
Randomized Comparison of DAT Versus ADE as Induction Chemotherapy in Children and Younger Adults With Acute Myeloid Leukemia. Results of the Medical Research Council's 10th AML Trial (MRC AML10)
Blood,
April 1, 1997;
89(7):
2311 - 2318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Dombret, C. Chastang, P. Fenaux, J. Reiffers, D. Bordessoule, R. Bouabdallah, F. Mandelli, A. Ferrant, G. Auzanneau, H. Tilly, et al.
A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
N. Engl. J. Med.,
June 22, 1995;
332(25):
1678 - 1683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Mayer, R. B. Davis, C. A. Schiffer, D. T. Berg, B. L. Powell, P. Schulman, G. A. Omura, J. O. Moore, O. R. McIntyre, E. Frei, et al.
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
N. Engl. J. Med.,
October 6, 1994;
331(14):
896 - 903.
[Abstract]
[Full Text]
|
|
|
|
|
